7NS0 Stock Overview
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Palisade Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.01 |
| 52 Week High | US$30.82 |
| 52 Week Low | US$4.75 |
| Beta | 1.35 |
| 1 Month Change | 0% |
| 3 Month Change | -16.76% |
| 1 Year Change | -76.88% |
| 3 Year Change | -99.78% |
| 5 Year Change | n/a |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7NS0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 2.0% |
| 1Y | -76.9% | -22.6% | 5.9% |
Return vs Industry: 7NS0 underperformed the German Pharmaceuticals industry which returned -22.6% over the past year.
Return vs Market: 7NS0 underperformed the German Market which returned 6% over the past year.
Price Volatility
| 7NS0 volatility | |
|---|---|
| 7NS0 Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7NS0's share price has been volatile over the past 3 months.
Volatility Over Time: 7NS0's weekly volatility has decreased from 29% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 9 | J. Finley | www.palisadebio.com |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy.
Palisade Bio, Inc. Fundamentals Summary
| 7NS0 fundamental statistics | |
|---|---|
| Market cap | €4.91m |
| Earnings (TTM) | -€11.42m |
| Revenue (TTM) | €231.75k |
21.2x
P/S Ratio-0.4x
P/E RatioIs 7NS0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7NS0 income statement (TTM) | |
|---|---|
| Revenue | US$250.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$250.00k |
| Other Expenses | US$12.57m |
| Earnings | -US$12.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.47 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,926.40% |
| Debt/Equity Ratio | 1.4% |
How did 7NS0 perform over the long term?
See historical performance and comparison